CN104042895A - Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof - Google Patents
Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof Download PDFInfo
- Publication number
- CN104042895A CN104042895A CN201410303932.3A CN201410303932A CN104042895A CN 104042895 A CN104042895 A CN 104042895A CN 201410303932 A CN201410303932 A CN 201410303932A CN 104042895 A CN104042895 A CN 104042895A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- lupus erythematosus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention belongs to the technical field of traditional Chinese medicines and relates to a traditional Chinese medicine composition for treating systemic lupus erythematosus. The traditional Chinese medicine composition for treating systemic lupus erythematosus provided by the invention is prepared from the following raw materials in parts by weight: 10-12 parts of Chinese angelica, 5-8 parts of root of rehmannia, 6-9 parts of pseudo-ginseng, 3-5 parts of Radix Ophiopogonis, 10-12 parts of achyranthes root, 10-12 parts of lithospermum, 3-5 parts of Caulis Spatholobi, 3-5 parts of cortex moutan, 10-12 parts of Salvia miltiorrhiza, 8-10 parts of lucid ganoderma, 6-9 parts of glossy privet fruit and 10-12 parts of Codonopsis. The treatment medicine is obvious in curative effect, safe and reliable, and has wide clinical application prospect.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of Chinese medicine composition and medical usage thereof of systemic lupus erythematosus.
Background technology
Systemic lupus erythematosus (sle) (systemic lupus erythematosus, SLE) be a kind of diffusivity, general autoimmune disease, mainly involve mucocutaneous, skeletal muscle, kidney and central nervous system, also may involve lung simultaneously, heart, multiple organs such as blood and system, show various clinical symptoms, its cause of disease and pathogeny are still not clear, in Serum in Patients with SLE, multiple autoantibody and crucial immunological abnormality can be detected, abnormal and the cytokine profiles secretion of lymphocyte function is unbalance to play an important role in the developing of this disease, studies confirm that in lupus erythematosus patients peripheral blood, CD3+CD4+T cell declines, CD3+CD8+T rises, IL-10 level raises, wherein IL-10 receives much attention in SLE pathogenesis as the representative of Th type cytokines.Interleukin is the polypeptide class that adjusting Growth of Cells, differentiation, the mediation signal of a large non-homogeneous of class transmits, and IL-10 is more concerned in systemic lupus erythematosus (sle) research.
Doctor trained in Western medicine is controlled systemic lupus erythematosus (sle) and adopts more the therapy of hormone, hormone is controlled systemic lupus erythematosus (sle) and is had distinguished curative effect, but hormone has sizable side effect, and long-term a large amount of use hormone is unfavorable for patient's physical and mental health, moreover, subtracting of hormone stops very likely causing aggravation.Middle treatment systemic lupus erythematosus (sle) adopts the way of Chinese drugs dispensing more, has distinguished curative effect though Chinese drugs dispensing is controlled systemic lupus erythematosus (sle), and curative effect only rests on relief of symptoms side, is difficult to fundamentally systemic lupus erythematosus (sle) be treated.
Middle treatment systemic lupus erythematosus (sle) is a long-term process, just sees curative effect after generally adhering to treating half a year.Therefore, all there is certain limitation in the Therapeutic Method of systemic lupus erythematosus (sle) at present.Therefore, finding a kind of new active drug carrys out systemic lupus erythematosus patient and has very important meaning.
Summary of the invention
In order to make up the deficiencies in the prior art, the misery of mitigation system patients with SLE, the invention provides a kind of Chinese medicine composition of systemic lupus erythematosus, and it is evident in efficacy, safe and reliable, has wide potential applicability in clinical practice.
Technical scheme of the present invention is:
A Chinese medicine composition for systemic lupus erythematosus, this Chinese medicine composition is made up of the raw material of following weight portion: Radix Angelicae Sinensis 10-12 part, Radix Rehmanniae 5-8 part, Radix Notoginseng 6-9 part, Radix Ophiopogonis 3-5 part, Radix Achyranthis Bidentatae 10-12 part, Radix Arnebiae (Radix Lithospermi) 10-12 part, Caulis Spatholobi 3-5 part, Cortex Moutan 3-5 part, Radix Salviae Miltiorrhizae 10-12 part, Ganoderma 8-10 part, Fructus Ligustri Lucidi 6-9 part, Radix Codonopsis 10-12 part.
When being classified as the root of umbelliferae angelica.Another name: Radix Angelicae Sinensis, cloud are returned, western Radix Angelicae Sinensis, Min Radix Angelicae Sinensis.Enrich blood and invigorate blood circulation, menstruction regulating and pain relieving, loosening bowel to relieve constipation.For blood deficiency and yellow complexion, dizzy cardiopalmus, menoxenia, amenorrhea dysmenorrhea, asthenia cold abdominalgia, dryness of the intestine constipation, rheumatic arthralgia, injury from falling down, ulcer sores.Intenseness of heat bleeding patients is prohibited clothes, wet fullness in the epigastrium and abdomen and the careful clothes of diarrhea with loose stool person contained.
Radix Rehmanniae sweet in the mouth, hardship, be slightly cold, GUIXIN, liver, kidney channel, nourishing YIN and clearing away heat; Removing heat from blood is enriched blood.Main calentura excessive thirst; Interior-heat is quenched one's thirst; Hectic fever due to YIN-deficiency consumptive fever; Epidemic febrile disease is sent out speckle; Haematemesis due to heat in blood; Metrorrhagia; Hematuria; Have blood in stool; Blood deficiency and yellow complexion; Dizzy cardiopalmus; Insufficiency of blood amenorrhea.
Radix Notoginseng, is the root of Araliaceae Panax pseudoginseng (Panax seudo-ginseng), mildly bitter flavor, warm in nature, energy hemostasis, dissipating blood stasis, detumescence, analgesic therapy.
Radix Ophiopogonis, has another name called Radix Ophiopogonis, is Liliaceae Ophiopogon plant.Be used as medicine Radix Ophiopogonis with tuber.Nature,taste and action: sweet, micro-hardship, cool, Yin-nourishing and body fluid promoting, nourishing the lung to arrest cough, relieving restlessness clears away heart-fire.Cure mainly consumption of body fluid caused by febrile disease, vexed, thirsty, dry pharynx lung-heat, cough, pulmonary tuberculosis.
Radix Achyranthis Bidentatae is the plant of Amaranthaceae Achyranthes, and its property bitter but sweet flavor acid is flat, has promoting blood circulation to restore menstrual flow, invigorating the liver and kidney, bone and muscle strengthening, inducing diuresis for treating stranguria syndrome, draws the descending effect of blood (fire), be usually used in treating the gynaecopathia such as the amenorrhea, dysmenorrhea, menoxenia, puerperal abdonimal pain of stagnation of blood stasis, traumatic injury, the soreness of waist and knee joint of suffering from a deficiency of the kidney, weakness of the lower extremities, hematuria; dysuria, Urethra astringent pain and intimately go up the diseases such as headache that inflammation causes, dizzy, haematemesis, epistaxis.
Radix Arnebiae (Radix Lithospermi) is the root of comfrey Radix Arnebiae (Radix Lithospermi) (Lithospermumerythrorhizon), cold in nature, bitter in the mouth, enter percardium, Liver Channel, can removing heat from blood, invigorate blood circulation, heat-clearing and toxic substances removing, cure mainly warm macule, jaundice due to damp-heat, purpura, tells, (blood is ugly), hematuria, stranguria with turbid discharge, constipation with heat retention, burn, eczema, erysipelas, gets treacle, hair key, clearing the nasal passage thoroughly, dispersing cold for relieving pain, dampness Detoxication.
Caulis Spatholobi is the rattan of pulse family Climbing Plant spatholobus suberectus, Millettia dielsiana, evergreen mucuna etc.Someone thinks that this medicine comes from supplementary Amplifications of the Compendium of Materia Medica, but examines its plant description and accompanying drawing from different now.Its name that really name conforms to reality comes from the Wang Ang of Qing Dynasty essentials of Matea Medica, and other this agrostology is also loaded with the another name such as " Radix seu Caulis Verntilaginis Leiocarpae ", " Caulis seu Radix Schisandrae Henryi ".Property bitter but sweet flavor temperature, returns Liver Channel, has promoting the circulation of blood to enrich blood, regulating menstruation, the effects such as relaxing muscles and tendons and activating QI and blood in the collateral, can treat that the gynaecopathia such as menoxenia, blockage of menstruation, dysmenorrhea, blood deficiency amenorrhea and rheumatic arthralgia, numb hand and foot, limbs are weak and limp, blood deficiency dull yellowish colored skin etc., and controlling leukopenia also has certain curative effect.
Cortex Moutan is Cortex Moutan, is the dry root bark of ranunculaceae peony.Compendium of Material Medica: " nourishing YIN to lower pathogenic fire is separated speckle poison, throat, diuresis stasis.Descendant specially controls fire mutually with yellow tiller, does not know that the merit of Cortex Moutan more wins also.Red colored person's profit, the person of spending in vain mends, and people also seldom realizes, and should distinguish it." modern study, contained paeonol and glucosides constituents in addition thereof all have antiinflammatory action; The methanolic extract of Cortex Moutan has inhibition Platelet; Paeonol has the effects such as the central inhibitory actions such as calmness, cooling, antipyretic, analgesia, spasmolytic and atherosclerosis, diuresis, antiulcer.
Radix Salviae Miltiorrhizae has another name called Radix Salviae Miltiorrhizae, Radix Salviae Miltiorrhizae, Arisaema balansae Engl. etc.For dicotyledon Labiatae, dry root and rhizome.Main product in Anhui, the ground such as Henan, Shaanxi.Effect: promoting blood flow to regulate menstruation, stasis-dispelling and pain-killing, removing heat from blood eliminating carbuncle, the relieving restlessness that clears away heart-fire, nourishing blood to tranquillize the mind.
Ganoderma claims again Ganoderma lucidum seu Japonicum, Ganoderma, Ganoderma lucidum seu Japonicum, Herba mesonae chinensis, Ganoderma, is the Herb of Polyporaceae plant Ganoderma lucidum (Leyss. Ex Fr.) Karst. or Ganoderma.Property be sweet, flat.GUIXIN, liver, spleen, lung, the kidney Five Classics.Cure mainly asthenia, cough, asthma, insomnia, dyspepsia, malignant tumor etc.Modern pharmacology through scientific research institution many decades studies confirm that, Ganoderma, for strengthening body immunity, regulates blood glucose, controls blood pressure, auxiliary tumor chemoradiotherapy, and hepatoprotective, the aspects such as hypnotic all have significant curative effect.
Fructus Ligustri Lucidi is the fruit of Oleaceae Ligustrum plant Fructus Ligustri Lucidi.There is tonifying liver kidney yin, effect of crow palpus improving eyesight.Modern medicine study thinks that the effect that Fructus Ligustri Lucidi can suppress helicobacter pylori can treat gastropathy, also has and suppresses the treatment of purine abnormal metabolism for gout and hyperuricemia.For the hepatic and renal YIN deficiency, soreness of waist tinnitus, early whitening of beard and hair; Unseeing, poor vision; Fever due to yin deficiency, gastropathy and gout and and hyperuricemia.
Radix Codonopsis, sweet, flat.Return spleen, lung meridian.There is strengthening the spleen and tonifying the lung, effect of supplementing QI for promoting the production of body fluid.Can treat weakness of the spleen and stomach, anorexia and loose stool, limbs fatigue, the deficiency of the lung is breathed with cough, the spontaneous perspiration of breathing hard, deficiency of both QI and blood etc.
In Chinese medicine composition described above, can also contain Fructus Forsythiae 5-8 part and Rhizoma Anemarrhenae 12-15 part.These two kinds of Chinese medicines can further strengthen the therapeutic effect of the above-mentioned Chinese medicine composition of the present invention.Fructus Forsythiae: bitter in the mouth; Cold nature.Enter lung; The heart; Gallbladder meridian.Heat-clearing and toxic substances removing; Dispersing swelling and dissipating binds.Cure mainly anemopyretic cold; Epidemic febrile disease; Pyretic stranguria urine retention; Carbuncle; Toxic swelling; Scrofula; Goiter; Sore throat.Shennong's Herbal carries: " main cold and heat, scrofula, scrofula, carbuncle malignant boil, goiter, stagnation of pathogenic heat." clinic study shows; Fructus Forsythiae has broad-spectrum antibacterial action; staphylococcus aureus, Hayes dysentery bacterium are had to very strong inhibitory action; other pathogenic bacterium, influenza virus, fungus are had to certain inhibitory action; contained oleanolic acid has heart tonifying, diuresis and hypotensive activity; Citrin can reduce vascular permeability and fragility, prevents haemolysis, also has in addition that tell in antiinflammatory, town, anti-liver injury effect.Rhizoma Anemarrhenae hardship, sweet, cold.Return lung, stomach, kidney channel.There is clearing away heat-fire, promote the production of body fluid and moisturize.Clearing away heat-fire, the effect of promoting the production of body fluid and moisturizing.Be mainly used in fever caused by exogenous pathogenic factors, high hot excessive thirst, lung-heat type cough, osteopyrexia and fever, interior-heat is quenched one's thirst, dryness of the intestine constipation.
In Chinese medicine composition described above, preferably, its raw material by following weight portion of described Chinese medicine composition is made: 11 parts of Radix Angelicae Sinensis, 7 parts, the Radix Rehmanniae, 7 parts of Radix Notoginseng, 4 parts of Radix Ophiopogonis, 11 parts of Radix Achyranthis Bidentataes, 11 parts of Radix Arnebiae (Radix Lithospermi)s, 4 parts of Caulis Spatholobis, 4 parts of Cortex Moutans, 11 parts of Radix Salviae Miltiorrhizaes, 9 parts of Ganodermas, 8 parts of Fructus Ligustri Lucidi, 11 parts of Radix Codonopsis.Described Chinese medicine composition can also contain 13 parts of 6 parts of Fructus Forsythiaes and the Rhizoma Anemarrhenaes in addition.To thering is the most outstanding therapeutic effect in medicament for treating systemic lupus erythematosus.
The present invention also asks to protect above-mentioned Chinese medicine composition in the purposes of preparing in medicament for treating systemic lupus erythematosus.Drug effect embodiment 7 of the present invention shows, in the test of t lymphocyte subset cluster analysis, compared with SLE model group, the present invention can make the CD3+CD4+T cell that SLE sample mice declines rise, and the CD3+CD8+T rising is declined, and corrects the imbalance state of T cell subsets; In serum IL-10, the test of anti-ds-DNA antibody assay, compared with SLE model group, the present invention can significantly reduce the rising of SLE mice serum IL-10 and anti-ds-DNA antibody level, wherein dosage group and Normal group there was no significant difference in Chinese medicine composition, illustrates that medicine of the present invention is remarkable for SLE mice therapeutic effect; In the determination test of microdose urine protein, SLE model group albumin content obviously raises, reflection SLE mouse kidney has damage, the present invention can significantly reduce albuminous content in SLE mice urine, low, the middle dosage group of Chinese medicine composition effect is particularly remarkable, be better than positive drug, and low, the middle dosage group of Chinese medicine composition and Normal group there was no significant difference, show that damage has outstanding therapeutic effect to medicine of the present invention for SLE mouse kidney.
In order to express better Chinese medicine composition of the present invention, Chinese medicine composition of the present invention can be prepared into conventional clinically dosage form.Such as, the preparations such as powderous preparations, powder, pill, sublimed preparation, unguentum, granule, oral liquid, syrup, tablet, capsule, described pharmaceutical preparation all can prepare according to Chinese medicine preparation preparation method well-known to those skilled in the art.Preferably, Chinese medicine composition of the present invention is prepared into powder, water preparation, tablet or capsule according to conventional preparation technology.
The present invention also provides a kind of preparation method of Chinese medicine composition described above, it mainly comprises following step: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, doubly adding volumetric concentration according to the 4-9 of coarse powder gross weight is the alcoholic solution of 40%-95%, reflux, extract, three times, return time is 2-5h, filters, filtrate recycling ethanol, cold filtration, washes with water, after being dried, obtains Chinese medical concrete; Those skilled in the art can be at the technical conventional Chinese medicine pharmaceutical dosage form clinically for preparing of this preparation method, as tablet, capsule etc.
Chinese medicine composition of the present invention is aspect systemic lupus erythematosus, compared with prior art there is following advantage: compared with the chemotherapeutic agent of current treatment, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, and has improved patient's quality of life.In addition, in Chinese medicine composition of the present invention, contain multi-medicament component, action target spot is numerous, pharmacological evaluation shows that itself and existing Therapy for Systemic Lupus Erythematosus medicine have significant synergism aspect treatment, and can significantly reduce systemic lupus erythematosus disease, improve patient's compliance.
Detailed description of the invention
Further describe the present invention by specific embodiment below, but those skilled in the art should know, described embodiment does not also limit the present invention in any way.
(1) example of formulations part
Embodiment 1 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: 10 parts of Radix Angelicae Sinensis, 5 parts, the Radix Rehmanniae, 6 parts of Radix Notoginseng, 3 parts of Radix Ophiopogonis, 10 parts of Radix Achyranthis Bidentataes, 10 parts of Radix Arnebiae (Radix Lithospermi)s, 3 parts of Caulis Spatholobis, 3 parts of Cortex Moutans, 10 parts of Radix Salviae Miltiorrhizaes, 8 parts of Ganodermas, 6 parts of Fructus Ligustri Lucidi, 10 parts of Radix Codonopsis.
Get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, adding volumetric concentration according to 6 times of coarse powder gross weight is 75% alcoholic solution, reflux, extract, three times, and return time is 3h, filters, filtrate recycling ethanol, cold filtration, washes with water, obtains Chinese medical concrete after dry; Those skilled in the art can be at the technical conventional Chinese medicine pharmaceutical dosage form clinically for preparing of this preparation method, as tablet, capsule etc.
Embodiment 2 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: 12 parts of Radix Angelicae Sinensis, 8 parts, the Radix Rehmanniae, 9 parts of Radix Notoginseng, 5 parts of Radix Ophiopogonis, 12 parts of Radix Achyranthis Bidentataes, 12 parts of Radix Arnebiae (Radix Lithospermi)s, 5 parts of Caulis Spatholobis, 5 parts of Cortex Moutans, 12 parts of Radix Salviae Miltiorrhizaes, 10 parts of Ganodermas, 9 parts of Fructus Ligustri Lucidi, 12 parts of Radix Codonopsis.
Preparation method is with embodiment 1.
Embodiment 3 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: 11 parts of Radix Angelicae Sinensis, 7 parts, the Radix Rehmanniae, 7 parts of Radix Notoginseng, 4 parts of Radix Ophiopogonis, 11 parts of Radix Achyranthis Bidentataes, 11 parts of Radix Arnebiae (Radix Lithospermi)s, 4 parts of Caulis Spatholobis, 4 parts of Cortex Moutans, 11 parts of Radix Salviae Miltiorrhizaes, 9 parts of Ganodermas, 8 parts of Fructus Ligustri Lucidi, 11 parts of Radix Codonopsis.
Preparation method is with embodiment 1.
Embodiment 4 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: 10 parts of Radix Angelicae Sinensis, 5 parts, the Radix Rehmanniae, 6 parts of Radix Notoginseng, 3 parts of Radix Ophiopogonis, 10 parts of Radix Achyranthis Bidentataes, 10 parts of Radix Arnebiae (Radix Lithospermi)s, 3 parts of Caulis Spatholobis, 3 parts of Cortex Moutans, 10 parts of Radix Salviae Miltiorrhizaes, 8 parts of Ganodermas, 6 parts of Fructus Ligustri Lucidi, 10 parts of Radix Codonopsis, 5 parts of Fructus Forsythiaes, 12 parts of the Rhizoma Anemarrhenaes
Preparation method is with embodiment 1.
Embodiment 5 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: 12 parts of Radix Angelicae Sinensis, 8 parts, the Radix Rehmanniae, 9 parts of Radix Notoginseng, 5 parts of Radix Ophiopogonis, 12 parts of Radix Achyranthis Bidentataes, 12 parts of Radix Arnebiae (Radix Lithospermi)s, 5 parts of Caulis Spatholobis, 5 parts of Cortex Moutans, 12 parts of Radix Salviae Miltiorrhizaes, 10 parts of Ganodermas, 9 parts of Fructus Ligustri Lucidi, 12 parts of Radix Codonopsis, 8 parts of Fructus Forsythiaes, 13 parts of the Rhizoma Anemarrhenaes.
Preparation method is with embodiment 1.
Embodiment 6 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: 11 parts of Radix Angelicae Sinensis, 7 parts, the Radix Rehmanniae, 7 parts of Radix Notoginseng, 4 parts of Radix Ophiopogonis, 11 parts of Radix Achyranthis Bidentataes, 11 parts of Radix Arnebiae (Radix Lithospermi)s, 4 parts of Caulis Spatholobis, 4 parts of Cortex Moutans, 11 parts of Radix Salviae Miltiorrhizaes, 9 parts of Ganodermas, 8 parts of Fructus Ligustri Lucidi, 11 parts of Radix Codonopsis, 6 parts of Fructus Forsythiaes, 15 parts of the Rhizoma Anemarrhenaes.
Preparation method is with embodiment 1.
(2) drug effect embodiment part
Embodiment 7 impacts of Chinese medicine composition composition injection on systemic lupus erythematosus (sle) MRL/lpr mice
1.
experiment material
1.1 laboratory animals and grouping
60 of systemic lupus erythematosus (sle) in 8 week age (SLE) MRL/lpr mices, female, provided by Nanfang Medical Univ's Experimental Animal Center, adaptability was raised after one week, was divided at random 5 groups by body weight, 12 every group.12 of ICR mices, female, as Normal group mice.
Normal group: gavage gives solvent;
SLE model group: gavage gives solvent;
Prednisone group: gavage gives 5mg/kg;
Chinese medicine composition low dose group: gavage gives medicine 0.5mg/kg prepared by the embodiment of the present invention 1;
Dosage group in Chinese medicine composition: gavage gives medicine 1mg/kg prepared by the embodiment of the present invention 1;
Chinese medicine composition high dose group: gavage gives medicine 4mg/kg prepared by the embodiment of the present invention 1.
All test group administration every day 1 time, successive administration 3 weeks is got blood for subsequent use in the time that administration finishes, and wins spleen.
1.2 reagent
(1) IL-10, anti-ds-DNA antibody test kit are purchased from Beijing Bai Erdi biotech firm;
(2) PBS: take following reagent 8.5g NaCl, 0.2g KCl, 2.85g Na
2hPO
412H
2o, 0.27g KH
2pO
4, with 1L distilled water standardize solution, above reagent is to be all commercially available analytical pure;
(3) erythrocyte cracked liquid: first prepare 0.83%NH
4cl, then prepare tris solution (take tris 20.594g and be dissolved in 500-700ml distilled water, then with 1M HCl adjust pH 7.65 to 1L), 0.83%NH
4after Cl mixes in 9:1 ratio with tris solution and get final product;
(4) anti-mice fluorescent labeling monoclonal antibody CD3(FITC), be Beckman Coulter company product;
(5) anti-mice fluorescent labeling monoclonal antibody CD4(PE), CD8a(PE), Caltag laboratories product.
Experimental technique
2.1 t lymphocyte subset cluster analysiss
The preparation of splenocyte single cell suspension: the spleen of mice is put into the culture dish that fills cold PBS liquid and clean, in glass homogenizer, add 3mlPBS to grind, filter with 200 order stainless (steel) wires again, centrifugal spleen homogenate with rotating speed 1500rpm/min centrifugal 7 minutes, abandon supernatant, and add erythrocyte cracked liquid 2.5ml, mix, leave standstill and after 2 minutes, add again PBS liquid 2ml to stop lytic response, with 1500rpm/min centrifugal 7 minutes again, abandoning supernatant, adds PBS after washing three times with PBS, under fluorescence microscope, calculates cell number.Above operation all need be on ice.
With above splenocyte single cell suspension, after meter cell number, cell concentration is adjusted into 5 × 10
6cells/ml.Each group is got a wherein mouse boosting cell sample and is done subgroup analysis, and the mouse boosting cell sample of adjusted concentration is added to flow cytometry dedicated pipe, and every mouse boosting cell sample is prepared two pipes, and every pipe adds sample 100 μ l.
Add 5 μ lCD3(FITC at the first pipe that contains sample dedicated pipe) and 3 μ lCD4(PE), the second pipe adds 5 μ l CD3(FITC) and 3 μ l CD8(PE).Room temperature black out is hatched 20min, and each pipe adds 500 μ l sheath fluids, and vibration mixes.Machine analysis in preparation.
2.2 serum IL-10, anti-ds-DNA antibody assay
Press the operation of test kit operating instruction.
The mensuration of 2.3 microdose urine proteins:
Experiment reagent: 10%(v/v) glacial acetic acid solution (PH2.8); 0.303mol/L glycine-glacial acetic acid buffer (PH3.0): take 22.72g glycine, be diluted to 1000ml with 10% glacial acetic acid solution, add NaN
3100mg, room temperature sealing can be stablized 1 year; Bromophenol blue (1.924mmol/L) stock solution: accurately take 257.36mgBPB, molten to 200ml with dehydrated alcohol, 4 DEG C of refrigerators can be stablized 1 year; Bromophenol blue (0.231mmol/L) developer: get 60mlBPB stock solution, add 2.5mlTriton X-100, be diluted to 500ml with glycine-glacial acetic acid buffer, room temperature sealing can be preserved 1 year.
The collection of specimen and detection: in the 20th day, mice is put in metabolic cage and is raised respectively, collect 12 hours overnight urine, accurate recording urine amount.After sodium azide is processed, centrifugal (2000r/min) 10min, measures the mice urine 2ml of storage, respectively adds developer 1ml, mixes (preventing bubble), measures absorbance A with ultraviolet spectrophotometer under 600nm.The content size of absorbance A reflection microdose urine protein, A value is less, and microdose urine protein content is lower.
Experimental data is carried out statistical procedures in accordance with the following methods: adopt SPSS10.0 statistical software, with mean ± standard deviation, (x ± s) represent, many groups data relatively adopts variance analysis to calculating data, relatively adopts t inspection in group.With p < 0.05 for there being statistical significance.
Experimental result
The impact of 3.1 the present invention on SLE T lymphocyte subsets in spleen of mice immunized
CD3+CD4+ lymphocyte is helper T lymphocyte (Th), CD3+CD8+ lymphocyte mainly plays inhibition regulating action, SLE mouse model group CD3+CD4+ lymphocyte level is than the decline of Normal group, SLE mouse model group CD3+CD8+ lymphocyte level is than the rising of Normal group, the present invention can make the CD3+CD4+T cell that SLE mice declines rise, the CD3+CD8+T rising is declined, wherein in Chinese medicine composition, dosage group effect is better, this shows, medicine of the present invention can be corrected the imbalance state of SLE mouse T cell subgroup.Result of the test is in table 1.
The impact of table 1 the present invention on SLE T lymphocyte subsets in spleen of mice immunized
The impact of 3.2 the present invention on serum IL-10, anti-ds-DNA antibody content
With Normal group comparison, the IL-10 of SLE model mice and anti-ds-DNA antibody level obviously raise, compared with SLE model group, the present invention can significantly reduce SLE mice serum IL-10 and anti-ds-DNA antibody level, wherein low, the middle dosage group of Chinese medicine composition effect is particularly remarkable, be better than positive drug, wherein dosage group and Normal group there was no significant difference in Chinese medicine composition.This shows, medicine of the present invention is remarkable for SLE mice therapeutic effect.Result of the test is in table 2.
The impact of table 2 the present invention on SLE mice serum IL-10, anti-ds-DNA antibody content
*compared with Normal group, p < 0.05;
*compared with Normal group, p < 0.01;
#compared with SLE model group, p < 0.05;
# #compared with SLE model group, p < 0.01.
The impact of 3.3 the present invention on SLE mouse retention microalbumin content
, only there is minute quantity albumin in microalbuminuria reflection renal abnormality leaky protein, SLE model group albumin content obviously raises in Normal group urine, reflection SLE mouse kidney has damage; Compared with model group, the present invention can significantly reduce albuminous content in SLE mice urine, and low, the middle dosage group of Chinese medicine composition effect is particularly remarkable, is better than positive drug, and low, the middle dosage group of Chinese medicine composition and Normal group there was no significant difference.This further shows, for SLE mouse kidney, damage has outstanding therapeutic effect to medicine of the present invention.Result of the test is in table 3.
The impact of table 3 the present invention on SLE mouse retention microalbumin content (
)
*compared with Normal group, p < 0.05;
*compared with Normal group, p < 0.01;
#compared with SLE model group, p < 0.05;
# #compared with SLE model group, p < 0.01.
In the test of t lymphocyte subset cluster analysis, compared with SLE model group, the present invention can make the CD3+CD4+T cell that SLE sample mice declines rise, and the CD3+CD8+T rising is declined, and corrects the imbalance state of T cell subsets; In serum IL-10, the test of anti-ds-DNA antibody assay, compared with SLE model group, the present invention can significantly reduce the rising of SLE mice serum IL-10 and anti-ds-DNA antibody level, wherein dosage group and Normal group there was no significant difference in Chinese medicine composition, illustrates that medicine of the present invention is remarkable for SLE mice therapeutic effect; In the determination test of microdose urine protein, SLE model group albumin content obviously raises, reflection SLE mouse kidney has damage, the present invention can significantly reduce albuminous content in SLE mice urine, low, the middle dosage group of Chinese medicine composition effect is particularly remarkable, be better than positive drug, and low, the middle dosage group of Chinese medicine composition and Normal group there was no significant difference, show that damage has outstanding therapeutic effect to medicine of the present invention for SLE mouse kidney.
Claims (7)
1. a Chinese medicine composition for systemic lupus erythematosus, is characterized in that being made up of the raw material of following weight portion: Radix Angelicae Sinensis 10-12 part, Radix Rehmanniae 5-8 part, Radix Notoginseng 6-9 part, Radix Ophiopogonis 3-5 part, Radix Achyranthis Bidentatae 10-12 part, Radix Arnebiae (Radix Lithospermi) 10-12 part, Caulis Spatholobi 3-5 part, Cortex Moutan 3-5 part, Radix Salviae Miltiorrhizae 10-12 part, Ganoderma 8-10 part, Fructus Ligustri Lucidi 6-9 part, Radix Codonopsis 10-12 part.
2. the Chinese medicine composition of systemic lupus erythematosus as claimed in claim 1, is characterized in that: described Chinese medicine composition also contains Fructus Forsythiae 5-8 part and Rhizoma Anemarrhenae 12-15 part.
3. the Chinese medicine composition of systemic lupus erythematosus as claimed in claim 1, is characterized in that: its raw material by following weight portion of described Chinese medicine composition is made: 11 parts of Radix Angelicae Sinensis, 7 parts, the Radix Rehmanniae, 7 parts of Radix Notoginseng, 4 parts of Radix Ophiopogonis, 11 parts of Radix Achyranthis Bidentataes, 11 parts of Radix Arnebiae (Radix Lithospermi)s, 4 parts of Caulis Spatholobis, 4 parts of Cortex Moutans, 11 parts of Radix Salviae Miltiorrhizaes, 9 parts of Ganodermas, 8 parts of Fructus Ligustri Lucidi, 11 parts of Radix Codonopsis.
4. the Chinese medicine composition of systemic lupus erythematosus as claimed in claim 3, is characterized in that: described Chinese medicine composition also contains 13 parts of 6 parts of Fructus Forsythiaes and the Rhizoma Anemarrhenaes.
5. the Chinese medicine composition of the systemic lupus erythematosus as described in as arbitrary in claim 1-4, is characterized in that: described Chinese medicine composition is powder, water preparation, tablet or capsule.
6. the Chinese medicine composition of the systemic lupus erythematosus as described in as arbitrary in claim 1-4, the preparation method that it is characterized in that described Chinese medicine composition comprises following step: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, doubly adding volumetric concentration according to the 4-9 of coarse powder gross weight is the alcoholic solution of 40%-95%, reflux, extract, three times, return time is 2-5h, filters, filtrate recycling ethanol, cold filtration, washes with water, after being dried, obtains Chinese medical concrete; Those skilled in the art can be at the technical conventional Chinese medicine pharmaceutical dosage form clinically for preparing of this preparation method.
7. the arbitrary described Chinese medicine composition of claim 1-4 is in the purposes of preparing in medicament for treating systemic lupus erythematosus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410303932.3A CN104042895A (en) | 2014-06-30 | 2014-06-30 | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410303932.3A CN104042895A (en) | 2014-06-30 | 2014-06-30 | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104042895A true CN104042895A (en) | 2014-09-17 |
Family
ID=51496618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410303932.3A Pending CN104042895A (en) | 2014-06-30 | 2014-06-30 | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104042895A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104740404A (en) * | 2015-04-13 | 2015-07-01 | 杜卫卫 | Traditional Chinese medicine composition for treating lupus erythematosus |
| CN104825690A (en) * | 2015-05-30 | 2015-08-12 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating lupus nephritis and application thereof |
| CN106177335A (en) * | 2016-08-24 | 2016-12-07 | 南阳医学高等专科学校 | A kind of pharmaceutical composition of systemic lupus erythematosus and preparation method thereof |
-
2014
- 2014-06-30 CN CN201410303932.3A patent/CN104042895A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104740404A (en) * | 2015-04-13 | 2015-07-01 | 杜卫卫 | Traditional Chinese medicine composition for treating lupus erythematosus |
| CN104825690A (en) * | 2015-05-30 | 2015-08-12 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating lupus nephritis and application thereof |
| CN106177335A (en) * | 2016-08-24 | 2016-12-07 | 南阳医学高等专科学校 | A kind of pharmaceutical composition of systemic lupus erythematosus and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101347612B (en) | Compound medicament for treating common cold cough and acute/chronic bronchitis, and preparation method thereof | |
| CN101332284A (en) | Chinese traditional medicine composition for treating ulcerative colitis and its preparation method | |
| CN101310751A (en) | Traditional Chinese medicine composition for replenishing qi and blood, preparation method and quality control method thereof | |
| CN104547486A (en) | Traditional Chinese medicine preparation for treating anemia and qi-deficiency weakness and preparation process for traditional Chinese medicine preparation | |
| CN105434894A (en) | Method for preparing traditional Chinese medicine composition for treating systemic lupus erythematosus | |
| CN102145089B (en) | Traditional Chinese medicine for treating heart failure | |
| CN102048902B (en) | Hepatitis treating traditional Chinese medicine composition, extract and preparation method, application and formulation | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN104042895A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof | |
| CN103006989B (en) | Medical composition for treating diabetic nephropathy | |
| CN104173950A (en) | Chinese herbal medicine composition for treating prostatic cancer | |
| CN102652774B (en) | Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method | |
| CN107029173B (en) | Pharmaceutical composition for treating primary liver cancer | |
| CN101695562B (en) | Chinese medicinal composition for treating viral hepatitis and preparation method thereof | |
| CN103933386B (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof | |
| CN104116957B (en) | Pharmaceutical composition for treating organ fibrosis and preparation method and application thereof | |
| CN103948754B (en) | Drug for treating renal-deficiency humid-heat type chronic nephritis | |
| CN106110048A (en) | A kind of pharmaceutical composition treating acne | |
| CN103006891B (en) | Medicine composition for treating chronic renal failure | |
| CN102258626A (en) | Traditional Chinese medicine compound Tenghuanglin, preparation method and application thereof | |
| CN104706708B (en) | Red stilbene ethanol extract prevents and treats application and wherein effective component identification method in hepatic fibrosis medicines in preparation | |
| CN104352797A (en) | Traditional Chinese medicine for treating advanced lung cancer and application of traditional Chinese medicine | |
| CN104547514A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus rheumatoid arthritis vasculitis and application thereof | |
| CN103877509B (en) | A kind of medicine and its preparation method treating leukemia | |
| CN109172756B (en) | A Chinese medicinal composition for treating hepatopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Jianhua Inventor before: Liu Xuejian |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140917 |